胶质母细胞瘤
复制(统计)
压力(语言学)
生物
癌症研究
遗传学
哲学
病毒学
语言学
作者
Shaobo Wang,Yanhua Qi,Rongrong Zhao,Ziwen Pan,Boyan Li,Wei Qiu,Shulin Zhao,Xiaofan Guo,Shilei Ni,Gang Li,Hao Xue
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2024-01-29
标识
DOI:10.1093/neuonc/noae014
摘要
Abstract Background Glioblastoma (GBM) is characterized by chromosome 7 copy number gains, notably 7q34, potentially contributing to therapeutic resistance, yet the underlying oncogenes have not been fully characterized. Pertinently, the significance of long noncoding RNAs (lncRNAs) in this context has gained attention, necessitating further exploration. Methods FAM131B-AS2 was quantified in GBM samples and cells using qPCR. Overexpression and knockdown of FAM131B-AS2 in GBM cells were used to study its functions in vivo and in vitro. The mechanisms of FAM131B-AS2 were studied using RNA-seq, qPCR, Western blotting, RNA pull-down, coimmunoprecipitation assays, and mass spectrometry analysis. The phenotypic changes that resulted from FAM131B-AS2 variation were evaluated through CCK8 assay, EdU assay, comet assay, and immunofluorescence. Results Our analysis of 149 primary GBM patients identified FAM131B-AS2, a lncRNA located in the 7q34 region, whose upregulation predicts poor survival. Mechanistically, FAM131B-AS2 is a crucial regulator of the replication stress response, stabilizing RPA1 through recruitment of USP7 and activating the ATR pathway to protect single-stranded DNA from breakage. Furthermore, FAM131B-AS2 overexpression inhibited CD8+ T-cell infiltration, while FAM131B-AS2 inhibition activated the cGAS-STING pathway, increasing lymphocyte infiltration and improving the response to immune checkpoint inhibitors. Conclusion FAM131B-AS2 emerges as a promising indicator for adjuvant therapy response and could also be a viable candidate for combined immunotherapies against GBMs.
科研通智能强力驱动
Strongly Powered by AbleSci AI